Raymond James Analysts Cut Earnings Estimates for TSE:MDP

Medexus Pharmaceuticals Inc. (TSE:MDP) – Stock analysts at Raymond James reduced their Q3 2025 earnings per share estimates for Medexus Pharmaceuticals in a report issued on Tuesday, January 7th. Raymond James analyst M. Freeman now expects that the company will earn ($0.03) per share for the quarter, down from their previous estimate of $0.01. Raymond James has a “Strong-Buy” rating and a $4.00 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals’ current full-year earnings is $0.16 per share. Raymond James also issued estimates for Medexus Pharmaceuticals’ Q4 2025 earnings at ($0.06) EPS, FY2025 earnings at $0.03 EPS and Q1 2026 earnings at $0.23 EPS.

Several other equities analysts have also recently weighed in on MDP. Alliance Global Partners upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a research report on Monday, December 23rd. Leede Financial set a C$8.25 price objective on shares of Medexus Pharmaceuticals and gave the company a “speculative buy” rating in a research report on Monday, September 30th. Two equities research analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Strong Buy” and a consensus target price of C$5.25.

Medexus Pharmaceuticals Trading Down 0.7 %

Shares of MDP stock opened at C$4.04 on Friday. The firm’s 50 day moving average is C$2.77 and its 200 day moving average is C$2.53. The stock has a market capitalization of C$99.10 million, a P/E ratio of 80.80 and a beta of 1.96. Medexus Pharmaceuticals has a 12 month low of C$1.47 and a 12 month high of C$4.24.

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.